| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 03/04/2004 | WO2004017907A2 Blood clot-targeted nanoparticles |
| 03/04/2004 | WO2004017905A2 Method and apparatus for noninvasively evaluating endothelial function |
| 03/04/2004 | WO2003055442A3 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
| 03/04/2004 | WO2003032904A3 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 03/04/2004 | WO2003007986A3 Vaccine formulation potentiated by the combination of a dna and an antigen |
| 03/04/2004 | WO2002012502A9 Anti-tnf antibodies, compositions, methods and uses |
| 03/04/2004 | US20040044215 Crystallization, filtration; neurokinins receptor antagonist |
| 03/04/2004 | US20040044009 Drug abuse; cental nervous system disorders; cognition activators |
| 03/04/2004 | US20040043969 Tubulin binding agents and corresponding prodrug constructs |
| 03/04/2004 | US20040043936 Antiproliferative and antiviral proteins and peptides |
| 03/04/2004 | US20040043933 Mixture with pH moderator, antioxidant and Group 2a salt; anticoagulant |
| 03/04/2004 | US20040043418 Humanized antibodies that sequester Abeta peptide |
| 03/04/2004 | US20040043038 Vaccines |
| 03/04/2004 | US20040042967 Method of treating a systemic disease |
| 03/04/2004 | CA2499278A1 Method of preparing dry powder inhalation compositions |
| 03/04/2004 | CA2496572A1 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
| 03/04/2004 | CA2496097A1 Keto cannabinoids with therapeutic indications |
| 03/04/2004 | CA2495682A1 Method for the prevention and/or treatment of atherosclerosis |
| 03/04/2004 | CA2491758A1 Blood clot-targeted nanoparticles |
| 03/03/2004 | EP1394152A1 2-iminoimidazole derivatives (1) |
| 03/03/2004 | EP1394150A1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| 03/03/2004 | EP1392694A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors |
| 03/03/2004 | EP1392666A1 Biologically active methylene blue derivatives |
| 03/03/2004 | EP1392307A1 Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
| 03/03/2004 | EP1392133A2 Functional agent for decomposing nicotine and method of preparing the same |
| 03/03/2004 | CN1479624A Process for preparing aqueous extracts of plants and extracts so obtained |
| 03/03/2004 | CN1140535C Halo derivatives of 9-deoxo-9a-aza-9a-homery theromycin A. |
| 03/03/2004 | CN1140525C 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 03/03/2004 | CN1140516C Quinoline and quinoxaline compounds which inhibits platelet-derived growth factor on/or p56lck tyrosine kinases |
| 03/03/2004 | CN1140503C Triazepiones, compound process for their preparation and their therapeutic application |
| 03/03/2004 | CN1140252C Oxidation dyeing composition for keratin fibres and dyeing mehtod using said copmositions |
| 03/02/2004 | US6699891 Npyy5 antagonists |
| 03/02/2004 | CA2189007C Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof |
| 03/02/2004 | CA2138289C N-substituted azabicycloheptane derivatives, the preparation and use thereof |
| 02/26/2004 | WO2004016231A2 PROTECTION OF PATIENTS LACKING A FUNCTIONAL SPLEEN AGAINST S. PNEUMONIAE WITH PNEUMOCOCCAL SURFACE PROTEIN A (PspA) |
| 02/26/2004 | WO2004016230A2 Identification of the endothelial receptor for the angiostatin kringle-5 |
| 02/26/2004 | WO2004016227A2 Screening methods for cognitive enhancers |
| 02/26/2004 | WO2004016223A2 Assaying compounds or agents for microsomal prostaglandin e synthase or hematopoietic prostaglandin d synthase activity |
| 02/26/2004 | WO2004016222A2 Hepatitis c viral-like particle purification |
| 02/26/2004 | WO2004016219A2 Clinical assays for the detection and typing of human herpesviruses |
| 02/26/2004 | WO2004016218A2 Medical decision support systems utilizing gene expression and clinical information and method for use |
| 02/26/2004 | WO2004016101A2 Compositions comprising dietary fat complexer and methods for their use |
| 02/26/2004 | WO2003096973A3 A direct cellular energy delivery system |
| 02/26/2004 | WO2003092609A3 System and method of treating abnormal tissue in an organ having a layered tissue structure |
| 02/26/2004 | WO2003090692A3 Make-up applicator with led light source |
| 02/26/2004 | WO2003039476A3 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 02/26/2004 | WO2003032915A3 Viral inhibition by n-docosanol |
| 02/26/2004 | US20040039005 HIV replication inhibiting pyrimidines |
| 02/26/2004 | US20040038977 Treating arthritis, pain and cancer |
| 02/26/2004 | US20040038957 Anti-malarial activity |
| 02/26/2004 | US20040038935 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 02/26/2004 | US20040038916 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 02/26/2004 | US20040038855 Administering a compound which is a mammalian MCH1 receptor antagonist effective to treat the abnormality |
| 02/26/2004 | US20040038398 Purification and uses of dendritic cells and monocytes |
| 02/26/2004 | US20040037908 Dissolving a Simmondsins extract (Jojoba oil) in a solvent, adding a carbonaceous adsorbent, e.g., activated carbon; separating the adsorbent to obtain purified liquid extract; drying; anorexigenic agent; animal feed; organoleptic; |
| 02/26/2004 | US20040037828 Methods and pharmaceutical compositions for healing wounds |
| 02/26/2004 | US20040037812 Flowable implantable composition comprising a support material, such as various forms of collagen or alginate beads or threads, which can support the attachment and growth of chondrocyte cells thereto, ad a method of making a flowable |
| 02/26/2004 | US20040037775 Treating and preventing autoimmune diseases. The compositions and methods utilize peptides that are cell-specific. The peptides are conjugated to drugs. The peptide-drug conjugate can be internalized by the targeted cells thereby allowing for |
| 02/26/2004 | CA2835747A1 Compositions comprising dietary fat complexer and methods for their use |
| 02/26/2004 | CA2677430A1 Compositions comprising dietary fat complexer and methods for their use |
| 02/26/2004 | CA2495680A1 Hepatitis c viral-like particle purification |
| 02/26/2004 | CA2495391A1 Assaying compounds or agents for microsomal prostaglandin e synthase or hematopoietic prostaglandin d synthase activity |
| 02/25/2004 | EP1391456A1 2-iminoimidazole derivative (2) |
| 02/25/2004 | EP1391451A1 2-iminopyrrolidine derivates |
| 02/25/2004 | EP1390378A1 Pharmaceutically active uridine esters |
| 02/25/2004 | EP1390366A1 The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene |
| 02/25/2004 | EP1390349A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| 02/25/2004 | EP1390025A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 02/25/2004 | EP1087934B1 Aminocyclohexyl ether compounds and uses thereof |
| 02/25/2004 | CN1477975A Combination of GABA agonists and sorbitol dehydrogenase inhibitors |
| 02/25/2004 | CN1477970A 疫苗 Vaccine |
| 02/25/2004 | CN1139595C Crystalline macrolides and its preparation method |
| 02/25/2004 | CN1139404C Process for preparing iodinated organic X-ray contrast agents |
| 02/24/2004 | US6696606 Solid phase synthesis of arylretinamides |
| 02/24/2004 | US6696567 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/24/2004 | US6696481 Immediate-release tablets; treatment of arterial hypertension and heart failure |
| 02/24/2004 | US6696094 Herbal pharmaceutical composition for treatment of HIV/AIDS patients |
| 02/19/2004 | WO2004015072A2 Mrbs as modifiers of the rb pathway and methods of use |
| 02/19/2004 | WO2004014321A2 Compositions having a pearl blend appearance additive, personal care products made therefrom |
| 02/19/2004 | WO2004014319A2 Screening strategy for anticancer drugs |
| 02/19/2004 | WO2004014318A2 Levothyroxine compositions and methods |
| 02/19/2004 | WO2004014315A2 Selective plasma exchange therapy |
| 02/19/2004 | WO2004014314A2 Methods and compositions concerning poxviruses and cancer |
| 02/19/2004 | WO2004014306A2 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| 02/19/2004 | WO2004014303A2 Method of applying hyaluronic acid to implant or graft to enhance lubricity and cellular density |
| 02/19/2004 | WO2004014302A2 Mechanisms of myoblast transfer in treating heart failure |
| 02/19/2004 | WO2004014301A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 02/19/2004 | WO2004014298A2 Composition and method for lowering cholesterol |
| 02/19/2004 | WO2003045329A3 Methods for the purification of levofloxacin |
| 02/19/2004 | WO2002097072A8 Influenza vaccine composition |
| 02/19/2004 | US20040034230 Taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substitutions; anticarcinogenic agent |
| 02/19/2004 | US20040034087 Comprises phosphodiesterase inhibitor and beta-2-adrenoceptor agonist; for treatment of respiratory tract disorders |
| 02/19/2004 | US20040033982 Viral inhibition by n-docosanol |
| 02/19/2004 | US20040033585 Preparing tobbaco mosaic viral particles comprising therapeutic polypeptides for treatment of infectious diseases and tumors; immunotherapy; genetic vaccines |
| 02/19/2004 | US20040033233 Dried powder form in sachet or in capsule of root, bark and wood of Philippine Narra tree (Pterocarpus Indicus) |
| 02/19/2004 | US20040033226 Osteopontin, oligodendrocytes and myelination |
| 02/19/2004 | US20040031108 Hair dyeing agents containing indigo derivatives |
| 02/19/2004 | CA2818693A1 Methods and compositions concerning poxviruses and cancer |
| 02/19/2004 | CA2495935A1 Screening strategy for anticancer drugs |
| 02/19/2004 | CA2495112A1 Mechanisms of myoblast transfer in treating heart failure |